At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses follow-up data of the RESPONSE trial, which is a multicentre, open-label phase 3 study evaluating the efficacy and safety of ruxolitinib compared with best available therapy in patients with polycythemia vera resistant to or intolerant of hydroxyurea.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement